ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

FierceBiotechResmed snaps up Noctrix Health in $340M sleep tech deal

Endpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field

FierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Endpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic options

Endpoints NewsTango plans Phase 3 pancreatic cancer study after combo success

Endpoints NewsComing Soon

Endpoints NewsBiopharma's top-paid CEOs of 2025: 25 making $25M+

Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs

FierceBiotechBiopharma moves to reduce development risk earlier than ever

FierceBiotechIncyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda

Endpoints News#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot

FierceBiotechWhy Execution Excellence Now Defines Biopharma Winners